Help ?

IGMIN: We're glad you're here. Please click 'create a new query' if you are a new visitor to our website and need further information from us.

If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click 'take me to my Query.'

Browse by Subjects

Welcome to IgMin Research – an Open Access journal uniting Biology, Medicine, and Engineering. We’re dedicated to advancing global knowledge and fostering collaboration across scientific fields.

Members

Our goal is to inspire a culture of interdisciplinary dialogue that drives faster innovation.

Articles

Our goal is to inspire a culture of interdisciplinary dialogue that drives faster innovation.

Explore Content

Our goal is to inspire a culture of interdisciplinary dialogue that drives faster innovation.

Identify Us

Our goal is to inspire a culture of interdisciplinary dialogue that drives faster innovation.

IgMin Corporation

Welcome to IgMin, a leading platform dedicated to enhancing knowledge dissemination and professional growth across multiple fields of science, technology, and the humanities. We believe in the power of open access, collaboration, and innovation. Our goal is to provide individuals and organizations with the tools they need to succeed in the global knowledge economy.

Publications Support
[email protected]
E-Books Support
[email protected]
Webinars & Conferences Support
[email protected]
Content Writing Support
[email protected]
IT Support
[email protected]

Search

Explore Section

Content for the explore section slider goes here.

Abstract

Stephen Ahenkorah Editor at IgMin Research

Our goal is to inspire a culture of interdisciplinary dialogue that drives faster innovation.

Biography

Dr Stephen Ahenkorah holds PhD in Biomedical Sciences (Radiopharmacy) and currently works as an associate research scientist at the radiology department of the University of Iowa. Prior to this position he was a postdoctoral fellow at KU Leuven, Belgium where he developed an agent called 3p-C-NETA-TATE for targeting neuroendocrine tumors in vivo.

Research Interest

Development of radiopharmaceuticals for cancer treatment